ANDA 209243, held by Apotex. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 209243 (Doxycycline Hyclate), held by Apotex, was first approved by FDA on Apr 15, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2019 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Aug 26, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 15, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters